Search results
Results from the WOW.Com Content Network
The DrugBank Online website is available to the public as a free-to-access resource. However, use and re-distribution of content from DrugBank Online or the underlying DrugBank Data, in whole or part, and for any purpose requires a license. Academic users can apply for a free license for certain use cases while all other users require a paid ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13, used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis.
The most common side effects are reactions at the application site (including burning or stinging). [3] Crisaborole is a phosphodiesterase 4 (PDE-4) inhibitor, although its specific mechanism of action in atopic dermatitis is not known. [1] [2]
As of 17 April 2020, the application is still under review at the other agencies. [9] Tucatinib is a kinase inhibitor meaning it blocks a type of enzyme (kinase) and helps prevent the cancer cells from growing. [9] Tucatinib is approved for treatment after adults have taken one or more anti-HER2-based regimens in the metastatic setting. [9]
Daridorexant is indicated for the treatment of adults with insomnia characterized by difficulties with sleep onset and/or sleep maintenance. [1] The medication has been found to significantly improve latency to persistent sleep (LPS), wake after sleep onset (WASO), and subjective total sleep time (TST) in regulatory clinical trials. [1]
Parampanel did affect AMPA receptor desensitization, or the ratio of peak to late response to rapid application of AMPA. [17] Perampanel is a selective negative allosteric AMPA receptor antagonist of high-affinity and slow blocking kinetics, and is not use-dependent. Perampanel has a prolonged terminal half-life in humans of approximately 105 ...
Lixisenatide is used as adjunct to diet and exercise to treat type 2 diabetes. [3] In the European Union, its use is limited to complementing insulin therapy. [2] [4] As of 2017 it is unclear if they affect a person's risk of death.